TLX101 for Brain Cancer IPAX-1 Study Update
Melbourne (Australia) – 23 December 2019. Telix Pharmaceuticals has released an update on the progress of its TLX101 product in the treatment of glioblastoma multiforme
Telix Pharmaceuticals is pleased to release an update on the progress of its TLX101 product being developed for the treatment of glioblastoma multiforme (GBM, brain cancer). The IPAX-1 clinical trial, which is testing TLX101 combined with external beam radiation therapy in patients with recurrent GBM, is recruiting to plan. Early study outcomes appear encouraging.
To read the full media release please click here.